Results 71 to 80 of about 14,564 (189)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis

, 2013
Masahiro Miura,1,2 Takuya Iwasaki,1,2 Hiroshi Goto2 1Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan; 2Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, Japan Purpose: To ...
Iwasaki T, Goto H, Miura M
core  

Analytical Characterization for Similarity Assessment Between an Aflibercept Biosimilar SB15 and Reference Product (Eylea®)

Ophthalmology and Therapy
Introduction SB15 is a proposed biosimilar product of reference aflibercept (Eylea®), an approved biological drug product for retinal diseases including neovascular age-related macular degeneration (nAMD).
Hangyeore Lee, Jongcheol Huh, Dayoung Kim, Soye Lee, Jaeil Lee, Jungmin Lee, Beom Chan Kim, Jinsu Song   +7 more
doaj   +1 more source

Aflibercept as a second-line therapy in metastatic colorectal cancer: A limited Indian experience

Journal of the Scientific Society, 2016
Introduction: Aflibercept in combination with FOLFIRI has been shown to improve overall survival in the pivotal VELOUR study. Aflibercept has not yet been marketed in India.
Govind Babu, Umesh Das, Kuntejowdahalli Lakshmaiah, Lokanatha Dasappa, Linu Abraham Jacob, Suresh Babu   +5 more
doaj   +1 more source

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab

, 2015
Laurence S Lim,1,2 Wei Yan Ng,2 Ranjana Mathur,2 Doric Wong,2 Edmund YM Wong,2 Ian Yeo,2 Chui Ming Gemmy Cheung,2 Shu Yen Lee,2 Tien Yin Wong,2 Thanos D Papakostas,1 Leo A Kim1 1Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School,
Wong D, Cheung CM, Wong TY, Ng WY, Kim LA, Lee SY, Wong EY, Yeo I, Papakostas TD, Lim LS, Mathur R   +10 more
core  

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration

, 2017
Objectives: To evaluate anatomic and functional results after switching from intravitreal bevacizumab or ranibizumab treatment to aflibercept for wet (neovascular) age-related macular degeneration.
Abdullah Kaya, Ali Ayata, Cihan Büyükavşar, Tuncay Topal, Sercan Koray Sağdıç, Taner Kar, Melih Hamdi Ünal, Murat Sönmez, Yıldıray Yıldırım   +8 more
core   +1 more source

Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-analysis

Ophthalmology and Therapy
Introduction This systematic review and meta-analysis aimed to provide an updated evidence base for clinical decision-making by comparing the efficacy and safety of aflibercept 2 mg and ranibizumab in treating retinal vein occlusion (RVO).
Jing Wu, Xiaoning He, Fang Qi, Zhan Zhao, Zhe Xu, Hong Yan   +5 more
doaj   +1 more source

Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report

Case Reports in Ophthalmology, 2016
Background: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that responded on two separate occasions to intravitreal injections of aflibercept, despite previously demonstrating only minimal response
Stacey A. Strong, Avinash Gurbaxani, Michel Michaelides   +2 more
doaj   +1 more source

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study

, 2017
Andrii R Korol,1 Oleksandra Zborovska,2 Taras Kustryn,1 Oleksandra Dorokhova,2 Nataliya Pasyechnikova3 1Laser Department, 2Department of Inflammatory Pathology of the Eye, 3Filatov Institute of Eye Diseases and Tissue Therapy, National Academy
Kustryn T, Korol AR, Zborovska O, Dorokhova O, Pasyechnikova N   +4 more
core  

Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration

BMJ Open Ophthalmology
Purpose Age-related macular degeneration (AMD) remains the leading cause of blindness in developed countries. There are many different intravitreal anti-vascular endothelial growth factor (VEGF) drugs available for the treatment of neovascular AMD (nAMD).
Siegfried Priglinger, Jakob Siedlecki, Benedikt Schworm, Franziska Eckardt, Michael Hafner, Ben Asani, Caspar Liesenhoff, Alexander Kufner, Johannes Benedikt Schiefelbein   +8 more
doaj   +1 more source

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema

, 2017
Sameh Mosaad Fouda, Ahmed M Bahgat Department of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt Purpose: The purpose of this study was to compare the efficacy of intravitreal aflibercept and ranibizumab in the treatment of ...
Bahgat AM, Fouda SM
core